Top Section/Ad
Top Section/Ad
Most recent
Two big infrastructure deals with private capital providers are fuelling hopes of a sustained M&A rebound in Germany
SMG’s drop below offer price sends mixed signals
SMG pares back gains after year’s largest IPO, Verisure to follow
Italy’s top independent investment bank must try to survive inside Monte dei Paschi
More articles/Ad
More articles/Ad
More articles
-
Gland Pharma, a subsidiary of Shanghai Fosun Pharmaceutical Group, has set the final terms for its Rp64.8bn ($866.5m) IPO in India. -
Chinese biopharmaceutical firm RemeGen has raised HK$3.99bn ($514.7m) after pricing its IPO at the top of the marketed range, according to a source familiar with the matter.
-
The Shanghai bourse stunned the market on Tuesday after halting Ant Group’s $34bn IPO, a deal which was set to be the largest listing in history. The extraordinary move, likely spurred by comments from Ant’s co-founder Jack Ma that criticised authorities for stifling innovation in China, is expected to delay the listing by at least six months. It will also force investors to revalue the company.
-
Ozon, the Russian e-commerce company, has filed its initial paperwork for a US listing that could be squeezed in before the end of the year.
-
New Oriental Education & Technology Group is set to raise HK$10.1bn ($1.3bn) as it guides investors toward final pricing for its secondary offering in Hong Kong.
-
A new fund focused on renewable energy infrastructure is preparing to brave US election volatility by launching a £200m ($260m) IPO on the London Stock Exchange.
